ResearcherThe University of SydneyActive in the last 2 years
Dannel Yeo
Matched on ORCID iD 0000-0002-6546-1209; OpenAlex author ID A5040068110. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 2 papers
Papers 10
- Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer. Co-author DOI 10.1007/s00018-025-05669-x↗
- High mesothelin expression is associated with low cytotoxic T cell infiltration in pancreatic cancer. Last author DOI 10.3389/fimmu.2025.1651687↗
- The next wave of cellular immunotherapies in pancreatic cancer. Co-author DOI 10.1016/j.omto.2022.01.010↗
- Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells. Co-author DOI 10.3390/ijms23031671↗
- Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. Co-author DOI 10.1002/ijc.30615↗
- FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. Co-author DOI 10.1186/s12885-016-2057-z↗
- Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model. Co-author DOI 10.3109/08941939.2016.1160167↗
- The role of p21-activated kinases in pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000276↗
- Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases. Co-author DOI 10.1016/j.canlet.2014.01.001↗
- Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma. First author DOI 10.3109/08941939.2013.797057↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- John E.J. Rasko · 3 shared papers, 2022–2025 · strength 0.62
- Paper The next wave of cellular immunotherapies in pancreatic cancer. DOI 10.1016/j.omto.2022.01.010↗
- Paper Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer. DOI 10.1007/s00018-025-05669-x↗
- Paper Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells. DOI 10.3390/ijms23031671↗
- Peter Grimison · 2 shared papers, 2022–2025 · strength 0.40
- Hong Zhen He · 6 shared papers, 2013–2017 · strength 0.38
- Paper Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mi… DOI 10.1002/ijc.30615↗
- Paper The role of p21-activated kinases in pancreatic cancer. DOI 10.1097/mpa.0000000000000276↗
- Paper FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. DOI 10.1186/s12885-016-2057-z↗
- Mehrdad Nikfarjam · 6 shared papers, 2013–2017 · strength 0.38
- Paper Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mi… DOI 10.1002/ijc.30615↗
- Paper The role of p21-activated kinases in pancreatic cancer. DOI 10.1097/mpa.0000000000000276↗
- Paper FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. DOI 10.1186/s12885-016-2057-z↗
- Oliver Liang · 1 shared paper, 2025 · strength 0.28
- Charbel Sandroussi · 1 shared paper, 2025 · strength 0.21
- Phoebe A. Phillips · 1 shared paper, 2017 · strength 0.09
- Christopher Christophi · 2 shared papers, 2013–2014 · strength 0.08
- Andrew M. Lowy · 1 shared paper, 2016 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.